Liquidia has seen sharp swings in recent years, and the question now is whether the current share price lines up with what its earnings can reasonably support. With such a volatile backdrop, the issue is not just where the stock has come from, but what the current valuation assumes about the business from here.
-
Over the past 5 years the stock has delivered a very large gain, which puts extra focus on whether the present market value matches what the underlying earnings profile can justify.
-
The recent settlement with United Therapeutics, which includes US$380.7 million in payments over 2026 and 2027 and removes legal overhang on YUTREPIA sales for pulmonary arterial hypertension, may support clearer expectations for future profitability and cash generation.
-
The analysts covering Liquidia have run their own numbers. See what analysts think Liquidia's shares could be worth .
For investors, the debate is whether Liquidia's current price can be explained by its earnings when judged against the Fair Ratio benchmark.
If you want more ideas that link earnings power with price, a focused stock screen is a useful next step. Consider starting with 27 high quality undervalued stocks .
Where Does Liquidia Sit on Earnings?
The P/E ratio is a useful anchor for Liquidia because earnings are now a key part of how investors frame the story after the legal overhang shifted. On this lens, the stock trades on roughly 27.5x earnings, which is above the broader pharmaceuticals sector on about 15.6x yet sits below the peer group around 34.5x. That puts Liquidia at a richer level than the typical drug developer, but not at the top of the peer range.
The Fair Ratio, which reflects what investors might usually pay given the company's mix of growth prospects, profitability profile, size and risk, sits very close to where Liquidia currently trades. Because the recent settlement with United Therapeutics cleared a long running legal risk around YUTREPIA, the market appears willing to hold the shares on a P/E that is only slightly above this tailored benchmark. For readers, that suggests the present multiple does not obviously flag the stock as either sharply undervalued or clearly expensive on earnings alone. Explore the numbers behind Liquidia's P/E valuation .
The Liquidia Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St's Community page pick up where the valuation puzzle leaves off by spelling out which paths for Liquidia's growth, margins and earnings would need to play out for the stock to be worth materially more or less than today. Each narrative links its number to a clear view on how the business might evolve, with growth, profitability and risk assumptions that you can test again as fresh information comes through.
Bullish and bearish voices on Liquidia focus on the same legal reset but reach different conclusions about how much is now priced in.
Bull case: 20% undervalued
"Rapid early adoption of YUTREPIA, with more than 900 prescriptions and over 550 patient starts in about 11 weeks, points to growing physician and patient acceptance…"
Discover why this Narrative puts Liquidia at 20% undervalued .
Bear case: 29% overvalued
"Heavy dependence on a single drug franchise in a niche pulmonary hypertension market leaves the company exposed if clinical practice shifts toward alternative mechanisms or competing inhaled options…"
Explore why this Narrative puts Liquidia at 29% overvalued .
Liquidia's valuation still leaves one critical angle unexplored
Price and earnings only tell part of the story for Liquidia, because the research checks behind this profile have also highlighted specific risk signals that could change how you weigh everything else. Take a closer look at 2 warning signs (1 major) before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LQDA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
